Press releases

December 2nd 2013 - Xagenic Inc. Completes $20 Million Series B Financing

July 12th 2013 - Medicago announces agreement to be acquired by Mitsubishi Tanabe Pharma in a transaction valued at $357M

October 5th 2012 - Fonds de solidarité FTQ, CTI Life Sciences Fund and Ferring Pharmaceuticals Create a New Biotech in Québec

February 10th 2012 - Closing of acquisition of Enobia by Alexion - Yet another successful portfolio exit for CTI's Life Sciences Fund

Janvier 30th 2012 - Xagenic Inc. Closes $10 Million Series A Financing with CTI Life Sciences Fund, Ontario Emerging Technologies Fund (OETF) and QIAGEN N.V..

December 28th 2011 - Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP)

September 27th 2011 - Medicago Completes $25 Million Private Placement.

August 29th 2011 - Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies.

August 8th 2011 - Enobia Pharma Raises US $40 million.

April 5th 2011 - Medicago Announces Closing of $17.4 Million Equity Offering.

June 30th 2010 - Sanofi-aventis to acquire TargeGen Inc., a US biopharmaceutical company.

June 29th 2010 - Zymeworks Closes C$3.2M Round of Financing

February 11th 2010 - Somnus Therapeutics Closes US$15 Million Series A Financing with CTI Life Sciences and Care Capital

December 29th 2009 - NeurAxon Announces Closing of Convertible Debenture Financing

August 10th 2009 - Enobia Raises US$50M from Current Investors in Series C Financing

June 23rd 2009 - Zymeworks Closes C$3.4 million Financing Round and Announces Changes to its Board of Directors

October 15th 2007 - Chlorion Pharma Inc. Closes C$6.0 million Financing Round

September 11th 2007 - Enobia Pharma Inc. Closes C$40.1 million Series B Financing Round

July 12th 2007 - TargeGen Inc. Closes $40.0M Series D Financing Round

© CTI Life Sciences Fund L.P. All rights reserved.
“Where broad operational and venture capital experience come together to create and realize shareholder value in Life Sciences Companies with pre-clinical and clinical stage drugs and enabling technologies.”